Contact
Please use this form to send email to PR contact of this press release:
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
TO:
Please use this form to send email to PR contact of this press release:
Prothena Announces Initiation of Phase 2 PASADENA Study of PRX002/RG7935 in Patients with Early Parkinson’s Disease
TO: